Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo

N. J. Brown*, S. Nakamura, L. Ma, I. Nakamura, E. Donnert, M. Freeman, D. E. Vaughan, A. B. Fogo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

233 Scopus citations


Background. Aldosterone promotes nephrosclerosis in several rat models, whereas aldosterone receptor antagonism blunts the effect of activation of the renin-angiotensin-aldosterone system (RAAS) on nephrosclerosis, independent of effects on blood pressure. Based on recent findings linking activation of the RAAS with impaired fibrinolytic balance, we hypothesized that aldosterone induces sclerosis through effects on plasminogen activator inhibitor-1 (PAI-1), the major physiological inhibitor of plasminogen activation. Methods. We examined the effect of aldosterone antagonism on the development of sclerosis and on renal PAI-1 expression following radiation injury in the rat. Following a single dose of 12 Gy to the kidneys, male Sprague-Dawley rats were treated with placebo, the aldosterone antagonist spironolactone (4.5 mg/day by time-release subcutaneous pellet), the angiotensin type 1 receptor antagonist L158-809 (AT1RA; 80 mg/L drinking water), or combined spironolactone and AT1RA. Results. Rats treated with placebo developed significant proteinuria and nephrosclerosis 12 weeks following radiation associated with hypertension. Kidney PAI-1 mRNA expression was increased eightfold (P < 0.001 vs. nonradiated controls). Spironolactone alone had no effect on blood pressure (systolic blood pressure 149.0 ± 5.4 mm Hg) compared with placebo (151.6 ± 11.2 mm Hg, P = NS), whereas AT1RA alone (107.7 ± 8.9 mm Hg, P = 0.013 vs. placebo) or in combination therapy (102.1 ± 6.2 mm Hg, P = 0.001 vs. placebo) lowered blood pressure. Both the AT1RA and spironolactone decreased proteinuria following radiation (P < 0.001 vs. placebo for either drug), and the combination of AT1RA + spironolactone had a greater effect on proteinuria than spironolactone alone (P = 0.003). Aldosterone antagonism significantly decreased (P = 0.016 vs. placebo) and AT1RA virtually abolished (P = 0.001 vs. placebo) the development of sclerosis. Spironolactone significantly decreased PAI-1 mRNA expression in the kidneys of radiated animals (PAI-1 mRNA/GAPDH ratio 0.39 ± 0.13 vs. placebo 0.84 ± 0.05, P = 0.006), and there was a significant correlation between the degree of sclerosis and the level of PAI-1 immunostaining within individual rats (R2 = 0.97, P < 0.0001). Conclusion. This study is, to our knowledge, the first to demonstrate that aldosterone regulates PAI-1 expression in vivo, and supports the hypothesis that aldosterone induces renal injury through its effects on PAI-1 expression.

Original languageEnglish (US)
Pages (from-to)1219-1227
Number of pages9
JournalKidney international
Issue number3
StatePublished - 2000


  • Angiotensin
  • Fibrosis
  • Nephrosclerosis
  • Progressive renal disease
  • Renal injury
  • Renin
  • Spironolactone

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo'. Together they form a unique fingerprint.

Cite this